Comparison of pathological and biological features of symptomatic and mammographically detected ductal carcinoma in situ of the breast

Human Pathology

Volumn 30, Issue 8, 1999, Pages 943-948

  Walker, Rosemary A ^a   Dearing, Sheila J ^a   Brown, Louise A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

C erbB 2; Ductal carcinoma in situ; Early invasion; Mammographic screening; P53

Indexed keywords

ARTICLE; BREAST BIOPSY; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; METASTASIS POTENTIAL;

EID: 0032778032     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(99)90248-4     Document Type: Article

References (29)

1. Rosen PP: The pathological classification of human mammary carcinoma: Past, present and future. Ann Clin Lab Sci 9:144-156, 1979
2. Anderson TJ, Lamb J, Donnan P, et al: Comparative pathology of breast cancer in a randomised trial of screening. Br J Cancer 64:108-113, 1991
3. Bhathal PS, Brown RW, Lesueu GC, et al: Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 51:271-278, 1985
4. Nielsen M, Thomsen JL, Primdahl S, et al: Breast cancer and atypia among young and middle-aged women: A study of 110 medicolegal autopsies. Br J Cancer 56:814-819, 1987
5. Rosen PP, Braun DW Jr, Kinne DW: The clinical significance of pre-invasive breast carcinoma. Cancer 46:919-925, 1982
6. Page DL, Dupont WD, Rogers LW, et al: Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76:1197-1200, 1995
7. Lagios MD, Margolin FR, Westdahl PR, et al: Mammographically detected duct carcinoma in situ: Infrequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 63:618-624, 1989
8. Schwartz GF, Finkel GC, Garcia JC, et al: Subclinical ductal carcinoma in situ of the breast: Treatment by local excision and surveillence alone. Cancer 70:2468-2474, 1992
9. Lagios MD, Westdahl PR, Margolin FR, et al: Duct carcinoma in situ: Relationship of extent of non-invasive disease to the frequency of occult invasion, multicentricity, lymph node metastases and short-term treatment failures. Cancer 50:1309-1314, 1982
10. Patchefsky AS, Schwartz GF, Finkelstein SD, et al: Heterogeneity of intraductal carcinoma of the breast. Cancer 63:731-741, 1989
11. Bellamy COC, McDonald C, Salter DM, et al: Non-invasive ductal carcinoma of the breast: The relevance of histologie categorization. HUM PATHOL 24:16-23, 1993
12. Bobrow LG, Happerfield LC, Gregory WM, et al: Ductal carcinoma in situ: Assessment of necrosis and nuclear morphology and their association with biological markers. J Pathol 176:333-341, 1995
13. Quinn CM, Ostrowski JL, Parkin GJS, et al: Ductal carcinoma in situ of the breast: The clinical significance of histological classification. Histopathology 30:113-119, 1997
14. Ramachandra S, Machin L, Ashley S, et al: Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma: A detailed morphological analysis. J Pathol 161:7-14, 1990
15. BartkovaJ, Barnes DM, Millis RR, et al: Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. HUM PATHOL 21:1164-1167, 1990
16. Poller DN, Galea M, Pearson D, et al: Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. Breast Cancer Res Treat 20:3-10, 1991
17. Poller DN, Roberts EC, Bell JA, et al: p53 protein expression in mammary ductal carcinoma in situ: Relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. HUM PATHOL 24:463-468, 1993
18. National Coordinating Group for Breast Screening Pathology: Pathology Reporting in Breast Cancer Screening (ed 2). Sheffield, UK, National Health Service Breast Screening Programme, 1995, pp 22-27
19. Holland R, Peterse JL, Millis RR, et al: Ductal carcinoma in situ: A proposal for a new classification. Semin Diagn Pathol 11:167-180, 1994
20. Holland R, Hendricks JHCL, Verbeck ALM, et al: Extent distribution and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 335:519-522, 1990
21. van der Vijver MJ, Peterse JL, Mooi WJ, et al: Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245, 1988
22. Bobrow LG, Happerfield LC, Gregory WM, et al: The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 11:199-207, 1994
23. Zafrani B, Leroyer A, Fourquet A, et al: Mammographically detected ductal in situ carcinomas of the breast analyzed with a new classification: A study of 127 cases: Correlation with oestrogen and progesterone receptors, p53 and c-erbB-2 proteins and proliferative activity. Semin Diagn Pathol 11:208-214, 1994
24. Rudas M, Neumayer R, Grant MFX, et al: p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 33:39-44, 1997
25. Allred DC, Clark GM, Molina R, et al: Over expression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. HUM PATHOL 23:774-779, 1992
26. Walker RA, Dearing SJ, Lane DP, et al: Expression of p53 protein in infiltrating and in situ breast carcinomas. J Pathol 165:203-211, 1991
27. Munn KE, Walker RA, Menasce L, et al: Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ. Br J Cancer 74:1578-1585, 1996
28. Stratton MR, Collins N, Lakhani SR, et al: Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol 175:195-202, 1995
29. Walsh T, Chappell SA, Shaw JA, et al: Microsatellite instability in ductal carcinoma in situ of the breast. J Pathol 185:18-24, 1998